相关实验视频
Updated: Jul 9, 2025

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
6.7K
增加胰岛素分泌和葡萄糖的有效性在肥胖患者的2型糖尿病后腹部手术
Roberto Visentin1, Katrine Brodersen2, Bjørn Richelsen3
1Department of Information Engineering, University of Padova, Padova, Italy.
Journal of diabetes research
|November 29, 2023
概括
腹腔外科手术,如袖子胃切除术 (SG) 和Roux-en-Y胃绕道 (RYGB),通过增强胰岛素分泌和葡萄糖的有效性而不是胰岛素敏感性,可以改善2型糖尿病的葡萄糖耐受性.
科学领域:
- 代谢手术 代谢手术
- 内分泌学 在内分泌学.
- 糖尿病研究 糖尿病研究
背景情况:
- 2型糖尿病 (T2D) 的特征是β细胞功能障碍和胰岛素抵抗,导致葡萄糖不耐受.
- 腹腔外科手术,包括袖子胃切除术 (SG) 和Roux-en-Y胃绕道 (RYGB),促进减肥,改善胰岛素作用和β细胞功能.
- 肝脏胰岛素提取和葡萄糖的有效性是潜在的因素,有助于改善血糖耐受性后腹部手术.
研究的目的:
- 研究胰岛素分泌,胰岛素敏感性,葡萄糖有效性和肝脏胰岛素提取在RYGB和SG后早期葡萄糖耐受性改善中的作用.
- 为了比较RYGB和SG对2型糖尿病患者葡萄糖调节的代谢效应.
主要方法:
- 在手术前和手术后2个月,对9名RYGB和7名SG2D患者进行了口服葡萄糖耐受性测试 (OGTT).
- 八个健康的个体作为代谢对照.
- 使用口服最小模型分析了血葡萄糖,胰岛素,C-,GLP-1,GIP,胰岛素敏感性,胰岛素分泌,葡萄糖有效性和葡萄糖出现率.
主要成果:
- 无论是RYGB还是SG,都实现了显著的减重 (分别为13%和14%).
- 手术后两个月,胰岛素分泌和葡萄糖的有效性在两组中都显著改善,而胰岛素敏感性基本保持不变.
- 与对照组相比,腹部手术增加了GLP-1反应和肝脏胰岛素提取,GIP水平没有改变.
结论:
- 在肥胖T2D患者中,RYGB和SG后葡萄糖耐受性的早期改善主要是由增强的胰岛素分泌和葡萄糖有效性驱动的.
- 胰岛素敏感性在这些减肥手术后观察到的急性代谢改善中起到很小的作用.
- 临床试验注册:NCT02713555.5. 临床试验注册:NCT02713555.5. 临床试验注册:NCT02713555.5. 临床试验注册:NCT02713555.5. 临床试验注册:NCT02713555.5. 临床试验注册:NCT02713555.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
181
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
181
Carbohydrate Metabolism
11.2K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.2K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K

